Evidence method
Sequential · gp.financial.deposits
-2.72% · CORE · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
MTB · Mar 31, 2023
M&T BANK CORP. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-23-022068Bank
Evidence method
Yoy · gp.fundamentals.net_income
93.73% · CORE · VALID
Evidence method
Yoy · gp.financial.interest_expense
2012.45% · CORE · VALID
Evidence method
Yoy · gp.financial.interest_income
150.68% · CORE · VALID
Evidence method
Level · gp.fundamentals.cash
$1.8B · CORE · VALID
Evidence method
Sequential · gp.financial.loans
1.02% · CORE · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History26 statesSelf-history eligible
Dec 31, 20210/6 normalizedLevel 3Mar 31, 20221/6 normalizedLevel 3Jun 30, 20223/6 normalizedLevel 3Sep 30, 20223/6 normalizedLevel 3Dec 31, 20223/6 normalizedLevel 3Mar 31, 20236/6 normalizedLevel 3Mar 31, 20236/6 normalizedAmended as filedJun 30, 20236/6 normalizedLevel 3Sep 30, 20236/6 normalizedLevel 3Dec 31, 20236/6 normalizedLevel 3Mar 31, 20246/6 normalizedLevel 3Jun 30, 20246/6 normalizedLevel 3Sep 30, 20245/5 normalizedLevel 3Dec 31, 20245/5 normalizedLevel 3Mar 31, 20255/5 normalizedLevel 3Jun 30, 20255/5 normalizedLevel 3Sep 30, 20255/5 normalizedLevel 3Dec 31, 20255/5 normalizedLevel 3Mar 31, 20265/5 normalizedLevel 3Jun 30, 20265/5 normalizedLevel 4
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.